Josh Lipton examines some of the trending stories for investors to watch as part of today's Market Minute. Dell Technologies (DELL) stock pops as investors weigh a temporary tech tariff exemption. Pfizer (PFE) has announced that trials for its weight-loss pill are being halted. M&T Bank's (MTB) first quarter earnings were in line with analyst estimates, though the bank cut its full-year net interest income forecast. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. Video Transcript 00:00 Speaker A It's time for your Yahoo! Finance's market minute. US stocks trim gains as investors now await text current reprieve from President Trump's tariffs. Dell among the tech names getting a lift today. That's following exclusion of smartphones, computers and other consumer electronics from Trump's tariffs. However, confusion over the future of tariffs on China and on specific sectors continues to hang overhead. Pfizer announcing it's halting a late stage trial of its GLP1 pill candidate weight loss stocks such as Novo Nordisk and Eli Lilly getting a pop as Pfizer pauses its competing pill. And lastly, M&T Bank reporting first quarter results roughly in line with estimates, while looking ahead the bank did slash its net interest income forecast for the full year. However, Piper Sandler noting that guide revision was not surprising. And that's your Yahoo! Finance market minute. For more on what's trending on Yahoo! Finance, scan the QR code below. Related Videos 01:51 Crypto investing: What traders & long-term investors should know Yahoo Finance Video • 1 hour ago 02:10 Netflix's Q1 earnings out Thursday: What to expect Yahoo Finance Video • 2 hours ago 04:58 Apple Is Exempt From Trump's China Tariffs Bloomberg • 2 hours ago 01:43 Why you should focus on 'asset allocation' & avoid dip buying Yahoo Finance Video • 2 hours ago View Comments
Dell stock pops, Pfizer halts GLP-1 pill trial, M&T Bank outlook
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...